ClinicalTrials.gg
Active, not recruitingNCT06040320Updated Nov 12, 2026

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

A Phase 1/2 interventional study of Polatuzumab vedotin and Rituximab in Post-transplant Lymphoproliferative Disorder, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Washington University School of Medicine · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
138th of 171
12 · median 38
Started
2023
with 2 others
Phase 1/2
17 of 178
none open now
Primary completion
2026-11
later than 2 of 10 live
Registered
176th of 178
by date

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 138th largest by enrollment of the 171 interventional ones that give a count, is one of 3 that started in 2023, is one of 17 in phase 1/2, reaches primary completion later than 2 of the 10 other live ones, and was the 176th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study will test polatuzumab vedotin in combination with rituximab in patients with treatment-naïve CD20-positive post-transplant lymphoproliferative disorder (PTLD) based on the established efficacy of polatuzumab vedotin in B-cell lymphomas and the inadequate response rate of PTLD to single-agent rituximab. The hypothesis is that this combination therapy will be safe, well-tolerated, and effective. If so, patients with PTLD will be able to be spared the toxicity of anthracycline-based chemotherapy. Additionally, the role of the tumor microenvironment and the role of anellovirus, a non-human pathogen virus, will be explored as prognostic markers in PTLD.

03

Conditions studied

  • Post-transplant Lymphoproliferative Disorder

Keywords

  • PTLD
  • Non-Hodgkin's lymphoma
  • Risk stratification
  • Front-line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated -confirmed CD20-positive monomorphic post-transplant lymphoproliferative disorder (or CD20-positive lymphoma associated with immune deficiency) arising after solid organ or hematopoietic stem cell transplant. This may be defined by either the 2016 World Health Organization classification of lymphoid neoplasms or the 2022 International consensus Classification of Mature Lymphoid Neoplasms or the 2022 World Health Organization classification.
  • At least 18 years of age.
  • performance status ≤ 3.
  • Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator) as defined below:

    • ≥ 1.0 K/cumm
    • ≥ 75 K/cumm
    • ≥ 8.0 g/dL
    • Total \< 1.5 x IULN
    • (SGOT)/ALT(SGPT) \< 2.5 x IULN
    • > 30 mL/min measured or by Cockcroft-Gault
  • Note: Patients with extensive bone marrow involvement by lymphoma and/or disease-related cytopenias may be enrolled if the following criteria are met:

    • ANC ≥ 0.5 K/cumm
    • Platelets ≥ 50 K/cumm
    • Hemoglobin ≥ 7.0 g/dL
  • The effects of polatuzumab vedotin and rituximab on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect pregnancy while participating in this study, the participant must inform the treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document.

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system involvement with lymphoma / PTLD.
  • Current grade ≥ 2 peripheral neuropathy.
  • Current \< 40% on transthoracic echocardiogram or multigated acquisition (MUGA) scan
  • Subjects with history of concurrent second cancers requiring active, ongoing systemic treatment with the following exceptions:

    • Patients with non-melanoma skin cancer or carcinoma in situ of the cervix will not be excluded.
    • Patients with previous are eligible if disease-free for > 2 years.
    • Patients on long term hormonal therapy to prevent recurrence of a prior cancer (e.g., hormonal therapy for breast cancer) will not be excluded.
  • Currently receiving any other agents or received any investigational agents during the 4 weeks prior to the first dose of polatuzumab vedotin.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to polatuzumab vedotin, rituximab, or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (bacterial, fungal, viral, parasitic, or mycobacterial), interstitial lung disease, active non-infectious pneumonitis, congestive heart failure grade ≥ 3, unstable angina pectoris, or cardiac arrhythmia.
  • Pregnant and/or breastfeeding. Women of must have a negative serum or urine pregnancy test within 7 days prior to C1D1
  • Patients with are eligible provided the meet the following criteria:

    • On antiretroviral regimen and stable on that regimen
    • Healthy from an HIV perspective
    • > 250 cells/mcL
    • Minimal anticipated interactions or overlapping toxicity with polatuzumab vedotin or rituximab
    • HIV viral load \< 200 copies/mm3 by standard clinical assays
  • Active infection.

    • Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation.
  • Active infection.

    • Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation.
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Polatuzumab vedotin + Rituximab (Safety Lead-in Low Risk/Interim Complete Remission)

    * Cycle 1 (21 days) * Day 1: polatuzumab vedotin + rituximab * Day 8: rituximab * Day 15: rituximab * Cycle 2 (21 days) * Day 1: polatuzumab vedotin + rituximab * After Cycle 2, a response assessment will be performed. Patients who show a complete response (and are therefore determined to be low risk) will continue to receive polatuzumab vedotin + rituximab on Day 1 of each 21-day cycle for 4 additional cycles (6 cycles of treatment total).

    Drug: Polatuzumab vedotin · Drug: Rituximab

  • Experimental
    Polatuzumab vedotin + Rituximab (Expansion Low Risk/Interim Complete Remission)

    * Cycle 1 (21 days) * Day 1: polatuzumab vedotin + rituximab * Day 8: rituximab * Day 15: rituximab * Cycle 2 (21 days) * Day 1: polatuzumab vedotin + rituximab * After Cycle 2, a response assessment will be performed. Patients who show a complete response (and are therefore determined to be low risk) will continue to receive polatuzumab vedotin + rituximab on Day 1 of each 21-day cycle for 4 additional cycles (6 cycles of treatment total).

    Drug: Polatuzumab vedotin · Drug: Rituximab

  • Experimental
    Polatuzumab vedotin + Rituximab + CHP (Safety Lead-in High Risk/Lack of Interim Complete Remission))

    * Cycle 1 (21 days) * Day 1: polatuzumab vedotin + rituximab * Day 8: rituximab * Day 15: rituximab * Cycle 2 (21 days) * Day 1: polatuzumab vedotin + rituximab * After Cycle 2, a response assessment will be performed. Patients who show anything other than a complete response (and are therefore determined to be high risk) will receive polatuzumab vedotin + rituximab + CHP (cyclophosphamide + doxorubicin + prednisone) on Day 1 of each 21-day cycle for 4 additional cycles, followed by 2 final cycles of CHP alone on Day 1 (8 cycles of treatment total).

    Drug: Polatuzumab vedotin · Drug: Rituximab · Drug: CHP

  • Experimental
    Polatuzumab vedotin + Rituximab + CHP (Expansion High Risk/Lack of Interim Complete Remission)

    * Cycle 1 (21 days) * Day 1: polatuzumab vedotin + rituximab * Day 8: rituximab * Day 15: rituximab * Cycle 2 (21 days) * Day 1: polatuzumab vedotin + rituximab * After Cycle 2, a response assessment will be performed. Patients who show anything other than a complete response (and are therefore determined to be high risk) will receive polatuzumab vedotin + rituximab + CHP (cyclophosphamide + doxorubicin + prednisone) on Day 1 of each 21-day cycle for 4 additional cycles, followed by 2 final cycles of CHP alone on Day 1 (8 cycles of treatment total).

    Drug: Polatuzumab vedotin · Drug: Rituximab · Drug: CHP

Interventions

  • Given at 1.8 mg/kg

    Also known as: Polivy

  • Given at 375 mg/m\^2

    Also known as: Rituxan

  • DrugCHP

    Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)

06

What researchers measure

Primary outcomes

  1. Frequency and severity of treatment-related adverse events (AEs)

    Time frame: From start of treatment through 30 days after completion of treatment or initiation of alternative therapy (estimated to be 5-7 months)

  2. Number of dose-limiting toxicities (DLTs) (Safety Lead-In Cohort only)

    A dose-limiting toxicity (DLT) is defined as an occurrence of an adverse event delineated by the protocol that is at least possibly related to polatuzumab vedotin, rituximab, or the combination within Cycle 1 or Cycle 2.

    Time frame: From start of treatment through cycle 2 (estimated to be 42 days, each cycle is 21 days)

  3. Rate of completion of the regimen

    Time frame: Through completion of treatment (estimated to be 4-6 months)

Secondary outcomes

  1. Complete metabolic response (CR) rate by PET/CT

    -Per Lugano Response Criteria

    Time frame: After cycle 2 (estimated to be day 42, each cycle is 21 days)

  2. Complete metabolic response (CR) rate by PET/CT

    -Per Lugano Response Criteria

    Time frame: End of treatment (estimated to be between 4-6 months)

  3. Overall response rate (ORR)

    * Per Lugano Response Criteria * Overall Response Rate: The proportion of patients who have a complete or partial response to therapy.

    Time frame: End of treatment (estimated to be between 4-6 months)

  4. Best overall response

    * Per Lugano Response Criteria * Best Overall Response: Best response recorded from start of treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).

    Time frame: Through completion of treatment (estimated to be between 4-6 months)

  5. Duration of response

    * Per Lugano Response Criteria * Duration of Response: The time from onset of response to disease progression or death in patients who achieve complete or partial response.

    Time frame: Through 5 years from completion of treatment (estimated to be between 64 and 66 months)

  6. Progression-free survival (PFS)

    * Per Lugano Response Criteria * Progression-Free Survival: The time from initiation of treatment to the occurrence of disease progression or death.

    Time frame: Through 5 years from completion of treatment (estimated to be between 64 and 66 months)

  7. Overall survival (OS)

    -Overall Survival: The time from initiation of treatment to death.

    Time frame: Through 5 years from completion of treatment (estimated to be between 64 and 66 months)

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Nov 2026, 37 months.

Of 66 non-industry phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 110. This study's 37 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion May 2027 → Nov 2026 and completion May 2032 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2023
First posted
Sep 15, 2023
StartActual
Oct 4, 2023
Primary completionActual
Nov 6, 2026was May 2027
CompletionEst.
Oct 7, 2031was May 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2027→Nov 6, 2026 (actual)
Nov 12, 2026
Study completion
May 31, 2032→Oct 7, 2031
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion May 31, 2027→Nov 6, 2026 (now actual)
    Study completion May 31, 2032→Oct 7, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06040320
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Oct 4, 2023
Primary completion
Nov 6, 2026
Completion
Oct 7, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Neha Mehta-Shah, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polatuzumab vedotin · Rituximab

Start the discussion